2021
DOI: 10.1016/j.eclinm.2021.101158
|View full text |Cite
|
Sign up to set email alerts
|

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

5
69
2
5

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 73 publications
(81 citation statements)
references
References 31 publications
5
69
2
5
Order By: Relevance
“…72% of doses in Tyrol by the end of the study [14], compared to 16% with ChAdOx1-S and 10% with mRNA-1273) are in close agreement with the time trends following receipt of first and second dose vaccination previously reported for mRNA COVID-19 vaccines [15][16][17]. Given the limited phenotypic information available in our study, we could not investigate in detail why a small fraction of participants (0.4%) were nonresponders to full vaccination, but different immunocompromising conditions are associated with a lack in immunogenicity [18]. Nevertheless, substantially higher anti-S IgG levels were visible in younger individuals and individuals with prior SARS-CoV-2 infection, while lower anti-S IgG levels were detected among male participants and smokers.…”
Section: Discussionsupporting
confidence: 88%
“…72% of doses in Tyrol by the end of the study [14], compared to 16% with ChAdOx1-S and 10% with mRNA-1273) are in close agreement with the time trends following receipt of first and second dose vaccination previously reported for mRNA COVID-19 vaccines [15][16][17]. Given the limited phenotypic information available in our study, we could not investigate in detail why a small fraction of participants (0.4%) were nonresponders to full vaccination, but different immunocompromising conditions are associated with a lack in immunogenicity [18]. Nevertheless, substantially higher anti-S IgG levels were visible in younger individuals and individuals with prior SARS-CoV-2 infection, while lower anti-S IgG levels were detected among male participants and smokers.…”
Section: Discussionsupporting
confidence: 88%
“…Overall, 82 studies were included for meta-analysis ( table 1 , supplementary table 2). 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 …”
Section: Resultsmentioning
confidence: 99%
“…The current meta-analysis further stratified results according to seroconversion and antibody titres after a first dose and second dose. * Study by Rahav et al 27 included patients with solid cancers, haematological cancers, immune mediated inflammatory disorders, organ transplants, and HIV/AIDS. Study by Monin et al 28 included patients with solid cancers and haematological cancers.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…The mRNA vaccines for COVID-19 were developed more quickly than any other vaccine in history. The first one is from Pfizer/BioNTech mRNA vaccine (BNT162b2) with 95% efficacy in neutralizing COVID-19 symptoms in 44,000 participants (89). The second vaccination, known as Moderna mRNA-1273 vaccine, was found 94.1% effective in a study conducted in 30,000 subjects (90).…”
Section: Importance and Challenges Of Vaccine Developmentmentioning
confidence: 99%